DAPA-HF
2019
Dapagliflozin and Prevention of Adverse outcomes in Heart Failure
In 4,744 patients with HFrEF (with or without diabetes), dapagliflozin reduced worsening HF or CV death versus placebo.
Result
Efficacy: Worsening HF or CV deathHR 0.74
Below 1 favours dapagliflozin, above 1 favours placebo.
- Absolute difference
- 4.9 points
The absolute difference is derived from the event rates.
Also reported: Benefit independent of diabetes.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT, median 18 mo
- Relevance
- Practice-defining: a trial the guidelines cite as evidence.
- Source
- McMurray JJV, et al. N Engl J Med. 2019;381(21):1995-2008.doi 10.1056/NEJMoa1911303
Discussion & critique
Defined SGLT2i as a fourth GDMT pillar. EMPEROR-Reduced confirmed class effect. Dapagliflozin/empagliflozin now standard regardless of diabetes status.